Citation: | GUO Wei, WANG Chen, WANG Yuheng, GAO Xiangdong. Expression, purification and functional assay of rhIL23R-CHR[J]. Journal of China Pharmaceutical University, 2013, 44(6): 583-588. DOI: 10.11665/j.issn.1000-5048.20130619 |
[1] |
Zhou L,Ivanov II,Spolski R,et al.IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways[J].Nat Immunol,2007,8(9):967-74.
|
[2] |
Chen Y, Claire LL, Brent M, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis[J].J Clin Invest,2006,116(5):1 317-1 326.
|
[3] |
Miossec P,Kolls JK.Targeting IL-17 and TH17 cells in chronic inflammation[J].Nat Rev Drug Discov,2012,11(10):763-776.
|
[4] |
Bettelli E,Korn T,Oukka M,et al.Induction and effector functions of T(H)17 cells[J].Nature,2008,453(7 198):1 051-1 057.
|
[5] |
Ciofani M,Madar A,Galan C,et al.A validated regulatory network for Th17 cell specification[J].Cell,2012,151(2):289-303.
|
[6] |
Griffiths CE,Strober BE,van de Kerkhof P,et al.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis[J].N Engl J Med,2010,362(2):118-128.
|
[7] |
Sandborn WJ,Gasink C,Gao LL,et al.Ustekinumab induction and maintenance therapy in refractory Crohn′s disease[J].N Engl J Med,2012,367(16):1 519-1 528.
|